Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02908451 · ClinicalTrials.gov registry record · Phase 1
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
A Phase 1 study, sponsored by AbGenomics B.V Taiwan Branch.
- Terminated
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT02908451: Clinical Trial Phase 1 study, sponsored by AbGenomics B.V Taiwan Branch.
NCT02908451 is a Phase 1 study that was terminated before completion, run by AbGenomics B.V Taiwan Branch. The registered enrollment target is 39 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02908451, a Phase 1 study, was terminated before completion, sponsored by AbGenomics B.V Taiwan Branch.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.
Interventions
- BIOLOGICAL AbGn-107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2017-04-24 |
| Est. Completion | 2021-02-28 |
| Phase | Phase 1 |
Why NCT02908451 stopped before completion
NCT02908451 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 1 intervention - of which AbGn-107 is the first listed.
NCT02908451 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02908451 about?
NCT02908451 is a clinical study titled "A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer". This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancr...
What is the current status of trial NCT02908451?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2017-04-24. Estimated completion is 2021-02-28.
What interventions are being tested in trial NCT02908451?
The interventions under investigation include: AbGn-107 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02908451?
This trial is sponsored by AbGenomics B.V Taiwan Branch, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02908451's enrollment target sits among peer trials
39 1191st of 2000 higher than 804 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI